ABOUT AUTHOR
Hitesh Sharma*
Maharishi Arvind Institute of Pharmacy, Jaipur-302020, Rajasthan, India
*E-mail: hiteshsharma2187@gmail.com
Abstract
To achieve effective ocular therapy, an adequate amount of active ingredients must be delivered and maintain at the site of action within the eye. The anatomical structure and the protective physiological process of the eye exert a formidable defense against ophthalmic drug delivery, leads to poor precorneal drug loss results in poor ocular by availability and ultimately poor ocular therapy. Ophthalmic drug delivery is one of the most interesting and challenging endeavors facing the pharmaceutical scientists, the major problem encountered to pharmaceutical scientist is rapid precorneal elimination of the drug, resulting in poor bioavailability and therapeutic response, because of high tear fluid turnover and dynamics. To improve ophthalmic drug bioavailability, there are considerable efforts directed towards newer drug delivery systems for ophthalmic administration. Since Conventional delivery systems often result in poor bioavailability and therapeutic response because of high tear fluids turn over and dynamics cause rapid elimination of the drug from the eyes. Newer research in ophthalmic drug delivery systems is directed towards a amalgamation of several drug delivery technologies, that includes to build up systems which is not only extend the contact time of the vehicle at the ocular surface, but which at the same time slow down the removal of the drug.
Key words: Eye, In-Situ, Hydrogel, Ophthalmic